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ABSTRACT 
Background and aim: A large number of studies found an inverse association between light 
to moderate alcohol consumption and the risk of acute myocardial infarction (AMI) and heart 
failure (HF). Whether this consumption is associated with the risk of atrial fibrillation (AF) is 
less clear. Methodological shortcomings may limit causal inference in these studies, most 
importantly the “sick-quitter” bias and the confounding by social factors. Furthermore, how 
drinking frequency, binge- and problem drinking or beverage types may influence these 
associations is not well understood. The overall aim of this thesis is to contribute to a better 
understanding of the prospective associations between light-to-moderate alcohol intake and 
the risk of AMI, HF and AF by addressing the above described unresolved issues. 
Methods and results: The Nord-Trøndelag Health Study (HUNT) is a large Norwegian 
population-based study conducted in three waves. For study I and II, we used data from 
HUNT2 conducted in 1995 -1997. In HUNT2, 65 215 individuals (70% of the eligible) 
participated and were followed for AMI and HF. For study III and IV, HUNT3 conducted in 
2006-2008, was used: 50 807 individuals (54% of the eligible) participated and were 
followed for AF. In study III, 1 266 healthy individuals were selected randomly from HUNT3 
and had an echocardiography examination.  
The quantity, type and frequency of alcohol consumption were ascertained by questionnaires. 
Binge drinking, i.e. drinking ≥ five glasses in one sitting and problem drinking were assessed. 
To identify abstainers who were former drinkers, information from the preceding waves of 
HUNT, i.e. HUNT1 or HUNT2 were used. They were categorized as long-term abstainers, 
abstainers who were former drinkers, rare drinkers, and drinkers, who were further 
categorized based on average alcohol consumption in a two-week period. Information on 
socioeconomic position, demographics, smoking, physical activity, common chronic 
conditions, and anxiety and depression symptoms were assessed, and anthropometrics, blood 
pressure and blood lipids were measured. 
The average alcohol consumption in the HUNT was 3-4 grams per day. The quantity of 
alcohol consumption was inversely associated with the risk of AMI and HF (study I, II). 
There was no clinically meaningful association between light to moderate alcohol intake and 
LV function (study III). Compared to abstainers, drinkers who consumed over seven drinks 
per week had an increased risk of AF. However, when we excluded those who consumed 
alcohol over the recommended limits, i.e., > seven drinks per week for women and >14 
drinks per week for men and reported binge and/or problem drinking the attributable risk of 
alcohol consumption was negligible in this low-drinking population (study IV). Frequent, 
more evenly distributed alcohol consumption was more protective for AMI and HF than less 
frequent intake of the same quantity (study I, II). Among binge and/or problem drinkers, 
alcohol consumption was associated with a slightly increased risk of HF and worse LV 
structural characteristics (study II, III).  
 Conclusions: Light to moderate alcohol consumption, within the recommended limits was 
associated with a reduced risk of AMI and HF, but not with the risk of AF. While frequent 
low-level consumption is associated with the lowest risk of AMI and HF, binge drinking 
seems to be harmful even if the average alcohol intake is moderate. Alcohol consumption 
within the recommended limits may provide some cardiovascular benefits without increasing 
the risk of AF. 
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1 BACKGROUND 
Alcohol consumption is culturally and economically integrated into many societies. There is a 
vast public health interest in its effect on health. Heavy drinking, i.e., consuming on average 
above 60 g of alcohol for men and 40 g of alcohol per day for women [1], is apparently one 
of the major avoidable risk factors for several health outcomes and is responsible for 3.8% of 
deaths and for 4.6% of disability-adjusted life-years lost globally [2-4]. It is associated with 
an increased risk of injuries, infectious diseases, cirrhosis, several types of cancer, diabetes, 
dementia and neuropsychiatric diseases [1]. Heavy drinking during pregnancy is associated 
with an increased risk of foetal alcohol syndrome and several other adverse birth outcomes 
[1, 5]. Compelling evidence shows that individuals with alcohol use disorders have an 
increased risk of several adverse cardiovascular outcomes [3, 6-10], primarily cardiac 
arrhythmias, heart failure (HF) and stroke [11-15]. Heavy drinking has a clear cardio-toxic 
effect and may induce cardiomyopathy [3, 14, 16].  
On the other hand light to moderate alcohol consumption is associated with a lower risk of 
overall mortality and several common chronic diseases [17, 18]. Studies have reported a 
reduced risk of type-2 diabetes [19-21], dementia, Alzheimer disease [22, 23] and 
cardiovascular diseases (CVD) [10, 12, 13, 18, 24-26] among individuals consuming on 
average 10-40 g of alcohol per day compared to non-drinkers. According to the Global 
Burden of Alcohol Study, the maximal protection associated with alcohol consumption is 
around 6-10 g per day on average for both sexes [17]. The reversion point, where the net 
benefit equals its harm is at 10-20 g per day for women and at 35-40 g per day for men, 
which roughly corresponds to 1-2 and 3-4 drinks per day of average alcohol intake, 
respectively [17]. Other studies found that this turning point was at a slightly higher 
consumption level, at around 40 g per day in women and at around 60 g per day in men [1, 
25].  
The possible protective association between alcohol intake and the risk of CVD was first 
described in ecological studies that found lower cardiac mortality rates in countries where 
regular wine consumption is widespread [27]. The “French paradox” refers to the related 
phenomenon that in France, a country with a long tradition of drinking wine, the linear 
relationship between dietary fat intake and CVD, described in other countries could only be 
found after the adjustment for alcohol consumption. Since then, a large number of studies 
with individual-level data have been conducted to examine the association between alcohol 
consumption and CVD. Compelling evidence now shows that a light to moderate level of 
alcohol intake, approximately 10 to 40 g per day, is inversely associated with the risk of 
ischemic heart diseases (IHD) [12, 13, 24, 28, 29], HF [8, 30], cerebrovascular diseases [9, 
12] and peripheral arterial disease [10, 25, 26]. However, whether this association is causal, 
and what are the exact public health implications of these findings remain unclear due to a 
number of methodological problems in previous research. At the same time, the knowledge 
regarding the association between light to moderate alcohol consumption and some specific 
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CVD, most importantly atrial fibrillation (AF) and other supraventricular cardiac arrhythmias 
[7, 31, 32] is still limited. 
Cardiovascular diseases are the major causes of death and disability worldwide, as 
approximately 30% of global deaths are attributable to CVD [33]. In Europe, 45% of all 
deaths in 2016 were due to CVD, and more than 30% of these occurred under the age of 75 
[34]. A better knowledge of the effect of light to moderate alcohol consumption on CVD is of 
a great public health importance. Therefore, the focus of this thesis is to contribute to a better 
understanding of the associations between light to moderate alcohol consumption and the risk 
of AMI, HF and AF, using a large population-based study to account for some of the 
limitations of previous research. First, cardiovascular outcomes and their underlying 
pathology are described, followed by previous research regarding the association of light to 
moderate alcohol intake with each of these outcomes. Finally, the major methodological 
challenges of previous research are presented. 
1.1 CARDIOVASCULAR DISEASES INVESTIGATED IN THIS THESIS 
 Acute myocardial infarction 1.1.1
Acute myocardial infarction (AMI), a clinical expression of IHD, is one of the major 
contributors to the burden of diseases worldwide [35-37]. According to the Swedish National 
Board of Health and Welfare, in 2015, approximately 26,600 individuals had an AMI in 
Sweden (www.socialstyrelsen.se). Acute myocardial infarction occurs when the blood supply 
in coronary arteries is insufficient; which leads to localised ischemia in the heart muscle [37]. 
The diagnosis of AMI is based on the presence of symptoms such as chest pain, dyspnea, 
unexplained weakness and nausea, specific ECG changes and elevated cardiac enzyme levels 
[37].  
The underlying pathology of AMI is atherosclerosis for most cases. Atherosclerosis is a 
multifactorial disease of the arteries that causes a thickening and hardening of the 
endothelium and loss of elasticity of the arteries [38]. During the development of 
atherosclerosis, an initially physiologically adaptive and reversible thickening of the intima 
becomes a pathological process that results in fat accumulation in the endothelium and the 
development of atherosclerotic plaques [38, 39]. Atherosclerosis is considered an 
inflammatory disease, as low-grade chronic inflammation mediates all of its stages including 
initiation, plaque formation and thrombotic complications [39]. Disturbed cellular and 
endothelial expression of different adhesion molecules, the production of inflammatory 
cytokines and the oxidation of low-density lipoprotein (LDL) cholesterol play an essential 
role in triggering and maintaining inflammation in the endothelium [39-42]. Acute 
myocardial infarction often develops due to an atherosclerotic plaque rupture or erosion, 
when the thrombogenic material from the atherosclerotic plaque may occlude the coronary 
arteries [37, 41-43]. 
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  Heart failure and left ventricular dysfunction 1.1.2
Heart failure is a complex clinical syndrome which occurs when the pump function of the 
heart is impaired due to structural or functional cardiac impairments or injuries [44]. It may 
cause symptoms like swelling of the limbs, fatigue, increased breathing difficulties and 
exertion during physical activity [44, 45].  
The clinical diagnosis of HF is based on the presence of these symptoms, as well as on 
structural and functional changes of the heart observed with echocardiography and elevated 
natriuretic peptide levels [44]. HF affects approximately 26 million individuals worldwide. It 
is one of the leading reasons for hospitalisation in the Western world and causes huge 
healthcare expenditures [46, 47]. In Sweden, the estimated prevalence is 2.2% and the 
incidence is 3.8 per 1000 person-years [48]. It is especially frequent among those over 70 
years of age and is associated with high mortality and morbidity [44, 46].  
The pathophysiology of HF often involves myocardial injury that alters the loading and the 
biochemical environment of the myocytes, which results in disturbed biochemical signalling. 
This further results in cardiac remodelling and might later lead to left ventricular (LV) 
systolic and/or diastolic dysfunction and decreased cardiac output. Besides the functional and 
structural dysfunction of the myocardium, valvular diseases, peri- and endocardium 
anomalies, cardio-myopathies due to genetics or cardio-toxic agents as well as arrhythmias 
may also contribute to HF development [44]. 
Heart failure diagnoses include clinical symptoms that may be apparent, but asymptomatic 
LV functional and structural dysfunctions, which are strong precursors of HF can be detected 
by echocardiography before the first symptoms appear [44]. While a dilated LV wall and 
decreased ejection fraction are straightforward signs of functional impairment, in many cases 
the ejection fraction is largely preserved [44]. However, increased LV wall thickness, LV 
mass and/or left arterial size with subtle echocardiographic anomalies in systolic functional 
indices can be signs of cardiac functional and structural alterations of the myocardium [44].  
 Atrial fibrillation 1.1.3
Atrial fibrillation is the most common symptomatic cardiac arrhythmia [49, 50]. It usually 
manifests in rapid, irregular heartbeats, fluttering in the chest, palpitation, tiredness or 
shortness of breath, but it may also be ‘silent’ with no noticeable symptoms [49]. The 
diagnosis is primarily based on ECG recordings [49]. Atrial fibrillation affects 2-3% of the 
adult population in Europe and its incidence and prevalence are increasing [51, 52]. Most 
AFs are considered to be chronic conditions and require life-long treatment [49], and it 
increases overall mortality and morbidity [49, 50, 53, 54], as it is a strong risk factor for 
stroke and HF [49]. 
The primary underlying pathophysiological mechanisms in AF involve the structural and 
functional changes of the atrial wall, so-called atrial remodelling [55]. Atrial remodelling 
increases the likelihood of spontaneous arrhythmogenic mechanisms and susceptibility to 
external arrhythmogenic triggers such as heavy alcohol consumption [32, 55].  
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1.2 PREVIOUS RESEARCH ON ALCOHOL CONSUMPTION AND THE RISK OF 
AMI, HF AND AF 
 Alcohol consumption and the risk of IHD, AMI, HF and AF 1.2.1
Compelling evidence suggests that the association between the quantity of alcohol 
consumption and IHD has a J or U shape, i.e., light to moderate alcohol intake is associated 
with lower IHD risk compared to abstinence, while heavy drinking and alcohol use disorder 
is associated with an increased risk of IHD [12, 13, 24-26]. According to a meta-analysis 
from 2012, light to moderate alcohol intake, or 10-40 g per day on average, is associated with 
a 20-40% lower risk of IHD compared to non-drinking [24]. The amount of alcohol intake 
where the risk of IHD starts to increase in comparison with zero alcohol consumption is 
around 50-70 g per day [12, 24, 26]. 
Heavy drinking is a well-established risk factor for HF. Alcoholic cardiomyopathy is a 
relatively frequent condition among heavy drinkers that often leads to LV dysfunction 
through the direct toxic effect of alcohol on the myocytes [14, 16, 56-58]. Heavy alcohol 
consumption may cause cardiac fibrosis that can alter LV function [59]. However, persons 
consuming up to 14 drinks per week seem to have an approximately 20% lower risk of HF 
compared to non-drinkers [8, 15, 30, 60]. As IHD contributes the most to the aetiology of HF, 
it is not clear whether the observed protective association between light to moderate alcohol 
intake and HF is mediated through its protective effect on IHD, or whether other biological 
mechanisms play a role as well [8, 30]. Studies that examine HF with ischemic and non-
ischemic aetiology separately only show the protective effect of light to moderate alcohol 
intake among ischemic HF cases [61]. The results are mixed with regard to light to moderate 
alcohol intake and LV function. Studies find better [58], or worse LV functional and 
structural characteristics [62], or no clinically relevant differences in LV function among 
those consuming up to 14 drinks per week compared to non-drinkers [63, 64]. 
Heavy alcohol consumption and alcohol use disorder are also associated with an increased 
risk of AF [7, 32, 65, 66]. Heavy alcohol intake influences the electrophysiological properties 
of the cardiomyocytes [32] and may cause electromechanical delay and increased 
sympathetic activity [32, 66-68]. However, it is unclear whether light to moderate alcohol 
consumption is associated with an increased risk of AF and whether there is a safe limit of 
alcohol intake up to which there is no meaningful AF risk increase [32]. While some suggest 
that alcohol intake is linearly associated with AF risk [69], others hypothesize that the 
association is curvilinear, i.e. that there is no increased risk up to a certain amount but a 
steeper increase in risk above a specific threshold [7, 31, 32, 70]. 
 Drinking frequency and binge drinking 1.2.2
The majority of previous studies assessed only the quantity of alcohol intake. However, the 
pattern of alcohol consumption might modify the association between the amount of alcohol 
consumption and CVD risk. Binge drinking, generally defined as consuming ≥ 4 drinks for 
women and ≥ 5 drinks for men in one single occasion at least once a month [71-73], is 
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harmful for cardiovascular health [28, 74, 75]. Studies show that a binge episode can increase 
the risk of acute coronary syndromes [29, 76] and supraventricular tachycardia within the 
first 24 hours after heavy alcohol consumption [1, 77]. This triggering effect of binge 
drinking on supraventricular tachycardia has been traditionally referred to as the “holiday 
heart symptom” [65]. Experimental studies found that acute alcohol infusion increases 
sympathetic nervous system activity, blood pressure and prothrombotic activity [28, 75, 76]. 
The increased release of catecholamines might trigger arrhythmias [57], and can directly 
damage the myocytes by inducing oxidative stress [57, 59, 78-80]. Binge drinking may alter 
the favourable association between alcohol consumption and IHD and HF even among 
moderate drinkers, consuming an average of 7-14 drinks per week [1, 25, 81]. It is also 
possible that the observed increase in AF among individuals, consuming within the 
recommended levels, at most 7 drinks per week for women and 14 drinks per week for men 
[82-84], may be due to the increased risk attributed to binge drinking.  
Studies show that evenly distributed frequent alcohol intake is associated with a more 
favourable IHD risk than less frequent intake of the same quantity [1, 25, 81]. Among 
drinkers consuming 7-14 drinks per week, those who report lower drinking frequency, 
consume a larger amount of alcohol on drinking days [85]. While the role of drinking 
frequency has been examined in relation to IHD, no previous study has investigated this in 
relation to HF or AF. 
 Beverage type 1.2.3
Whether the association between light to moderate alcohol intake and CVD differs according 
to beverage type is unclear, as well as whether the possible protective effects can be 
explained by alcohol itself or by other components of alcoholic beverages. Observational 
research concerning the effect of different beverage types on IHD risk yielded conflicting 
results. While some studies found a greater benefit among wine and beer drinkers compared 
to spirit drinkers [86-88], meta-analyses could not confirm that polyphenol-rich alcoholic 
beverages have a more positive effect [18]. In vitro biological studies show that polyphenols 
in wine have strong antithrombotic and antioxidant properties and also suppress inflammation 
[89-93]. Even alcohol-free wine stimulates antioxidant enzymes in human [94]. Polyphenols 
also modulate leukocyte adhesion molecules and improve gut microbiome [88, 91, 93]. 
However, the bioavailability of polyphenols in human is poor and only a small amount of the 
polyphenols in wine stay in active form and get into the bloodstream [92, 95, 96]. The 
examined favourable effect of wine might also be partly due to residual confounding. Wine 
drinkers usually have better education and health, have more favourable health-related 
behavioural patterns, and are more likely to follow a healthier drinking pattern than spirit 
drinkers. This may explain why previous findings are inconsistent concerning possible 
beverage-specific effects on CVD [97]. 
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 Methodological challenges 1.2.4
There is compelling evidence in support of the biological plausibility of the potential 
protective effect of light to moderate alcohol intake on atherosclerotic CVD; this includes 
increased HDL cholesterol level [88, 96, 98, 99], decreased inflammation [18, 88, 91, 100], 
decreased thrombotic activity [18, 101] and improved glycaemic control [93, 102-104] 
among other mechanisms. Nevertheless, there are no randomised controlled trials on light to 
moderate alcohol and risk of CVD as there are major ethical considerations against such a 
trial. The best evidence concerning this research question comes from observational studies, 
but there are several methodological considerations in relation to the results of these studies. 
While some of them are general concerns that can potentially affect all observational studies, 
others are more specific to this research field. In this thesis, we focus on the latter ones.  
1.2.4.1 Choice of reference group  
One of the most frequently discussed methodological aspects related to the inverse 
association between light to moderate alcohol consumption and CVD risk is related to the 
abstainer group [10]. In most Western countries the abstainer or non-drinker group is a mixed 
group which contains long-term abstainers and former heavy drinkers who stopped due to ill-
health [10, 105]. Abstinence from alcohol at baseline may be the consequence of a worsening 
health during the previous years, and the observed increased risk of these non-drinkers is due 
to their ill-health. The inclusion of abstainers who were former drinkers can bias the estimates 
considerably and this is often referred to as the “sick quitters bias” [105, 106]. Several studies 
have tried to reduce this problem by distinguishing between long-term abstainers and 
abstainers who were former drinkers. The simplest assessment of previous drinking habits is 
to ascertain it at baseline measurement; however, this is problematic as retrospective recall of 
previous alcohol consumption may not be accurate. As such, few studies have been able to 
assess alcohol consumption habits longitudinally and separate long-term abstainers and 
abstainers who were previous drinkers based on assessments prior to the baseline.  
1.2.4.2 Confounding due to cultural and social norms regarding alcohol consumption  
Moderate alcohol consumption is the socially accepted norm in many Western countries. 
Light to moderate drinkers are on average more educated, have higher income, better general 
health, fewer chronic conditions and better CVD risk profiles than abstainers and heavy 
drinkers [18, 97].They also have better social support, are more socially active and have 
better mental health than abstainers [97]. Long-term abstainers are often a very specific 
group, that might differ ethnically and culturally from rare- and light to moderate drinkers 
[25, 85, 107, 108]. There could be further characteristics that might differ between abstainers 
and light to moderate drinkers which are difficult to take into account. Therefore, residual 
confounding due to the unmeasured factors in these studies might lead to an overestimation 
of the possible protective effects of light to moderate alcohol intake on CVD [18]. On the 
other hand, light to moderate drinkers are more likely to be smokers than abstainers, and 
incomplete control of smoking habits may, in theory, lead to an underestimation of the 
protective effect. As the information on confounders is limited in traditional cohort studies, 
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some studies have used Mendelian randomisation to overcome this problem; in these studies 
genetic polymorphism is considered an instrumental variable for alcohol consumption [109]. 
However, the results of these studies varied, according to the chosen genetic polymorphisms 
[110, 111], which may indicate that some of the assumptions behind this method might have 
been violated. Unfortunately, these assumptions are difficult and sometimes impossible to 
evaluate [109]. Twin studies, which could control for shared genetic and environmental 
factors, confirmed the protective association between light to moderate alcohol intake and 
IHD risk [112]. 
 
  9 
2 AIMS OF THE THESIS 
The overarching aim of this thesis is to contribute to a better understanding of the 
associations between light to moderate alcohol intake and AMI, HF and AF by addressing the 
major methodological shortcomings in previous research, by using a large population-based 
cohort in Norway. The majority of the cohort participants were non- or very light drinkers, as 
non-drinking is more culturally acceptable in Norway than in other Western countries. As the 
population was surveyed three times during ten years, we had the opportunity to consider 
former alcohol consumption habits. 
The specific research questions are: 
1. Is light to moderate alcohol consumption associated with a lower risk of AMI? (Study I) 
2. Is light to moderate alcohol consumption associated with a lower risk of HF, and if so to 
what extent is this association explained by AMI? (Study II) 
3. Does drinking frequency or beverage type modify the association between alcohol 
consumption and AMI and HF, respectively? (Studies I and II) 
4. Is light to moderate alcohol consumption associated with a better LV function? How does 
binge drinking influence the association between alcohol intake and LV function? (Study III) 
5. Is light to moderate alcohol consumption associated with an increased risk of AF? Is 
alcohol consumption within the recommended limits still associated with an increased risk of 
AF? (Study IV) 
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3 MATERIALS AND METHODS 
3.1 STUDY POPULATION  
The HUNT study is a population-based cohort study that was conducted in three waves. 
(http://www.ntnu.edu/hunt). The first wave of HUNT (HUNT1) was conducted between 1984 
and 1986, the second wave (HUNT2) between 1995 and 1997 and the third wave (HUNT3) 
between 2006 and 2008 (Figure 1). On all three occasions, the whole adult population (aged 
above 20 years) of the Nord-Trøndelag County in central Norway was invited to participate. 
The first questionnaire and an information pamphlet for written consent were sent out to each 
individual. The studies were approved by the regional committee of ethics in medical 
research, the National Directorate of Health and the Norwegian Data Inspectorate [113]. 
Figure1. The HUNT studies and follow-up for the studies included in the thesis 
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 HUNT2 (studies I and II) 3.1.1
A total of 93 898 persons were invited to the second wave of the HUNT study, of which 65 215 
individuals participated. They completed questionnaires regarding their socio-demographic 
characteristics, health status, quality of life, chronic illnesses, and health behaviour. In the study 
centres, a standardised clinical examination was conducted by trained nurses, which included 
standard anthropometric measurements such as height, weight, hip and waist circumference, 
and blood pressure assessment. Blood and saliva samples were also taken [113]. All individuals 
participating in HUNT2 who had valid alcohol information and had no previous AMI were 
included in study I (n=58 827). Individuals with valid alcohol information and without previous 
HF were included in study II (n= 60 655) (Figure 2).  
Figure 2 Selection of study participants for studies I and II 
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 HUNT3 (study IV) 3.1.2
Altogether 93 860 adult residents of the Nord-Trøndelag County were invited to HUNT3 and, 
54.1% of them participated (Figure 3). As in HUNT2, data on sociodemographic factors, self-
reported health, chronic health conditions, and health-related behaviours were collected by self-
reported questionnaires. The same anthropometric and clinical measurements were assessed as 
in HUNT2, and blood and saliva samples were taken at the study centres. In study IV, we 
included 47 002 participants from HUNT3, who were free of previous AF and who provided 
valid answers concerning their alcohol consumption.  
Figure 3. Selection of study participants in studies III and IV 
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 The echocardiography study (study III) 3.1.3
A subsample of healthy individuals, (n=1 296) without known CVD, diabetes or hypertension 
was randomly selected from the HUNT3 cohort [114, 115] and underwent tissue Doppler and 
greyscale speckle tracking echocardiography. The inclusion criteria were validated by an 
experienced physician, and altogether 30 participants were excluded due to arrhythmias, 
myocardial or valvular pathology [114, 115]. In addition, for the current study, we excluded 
participants who did not provide valid data on alcohol consumption, resulting in 1 179 
participants included in study III (Figure 3). 
3.2 STUDY VARIABLES 
 Measures of alcohol consumption 3.2.1
In HUNT2 (studies I and II) alcohol consumption was measured with the following questions: 
(https://www.ntnu.edu/hunt/data/que): 
 “Concerning alcohol, are you a non-drinker?”  
 “How many times a month do you normally drink alcohol?” not including low-alcoholic 
beer, that contains less than 3.5% alcohol.  
 “How many glasses of beer (containing more than 3.5% alcohol by volume), wine or 
spirits do you usually drink in the course of two weeks”. 
Those who answered “yes”, or did not answer the first question but reported zero alcohol 
consumption on the third question were considered abstainers. Those who did not consider 
themselves non-drinkers, but reported zero alcohol consumption on the third question were 
categorized as rare-drinkers, i.e. consuming less than one drink in a usual two week period (or 
<0.5 drinks per week). Those who reported a minimum of one drink alcohol consumption 
during a usual two week period were categorised according to the amount of alcohol 
consumption: (i) ≥0.5 and ≤2.5, (ii) >2.5 and ≤5, (iii) >5 and ≤ 7 and (iv) >7 drinks per week. 
Daily alcohol consumption was also calculated using an average of 12 g alcohol per drinks [17]. 
The frequency of alcohol consumption was categorised based on the answer to the second 
question as: (i) less than once a month (abstainers and rare-drinkers), (ii) on one to four 
occasions in a month, (iii) on five or more occasions per month in study II. In study I, drinkers 
were categorized similarly except that the upper category was further classified as (iii) on five to 
12 occasions and (iv) on more than 12 occasions. 
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In HUNT3 (studies III and IV) the amount and the frequency of alcohol consumption were 
measured with the following three questions (https://www.ntnu.edu/hunt/data/que): 
 “About how often in the last 12 months did you drink alcohol?” 
 “Did you drink alcohol during the last 4 weeks?”  
 “How many glasses of beer (containing more than 3.5% alcohol by volume), wine or 
spirit do you usually drink in a course of two weeks? 
In studies III and IV, participants were categorised according to the quantity of alcohol 
consumption as: (i) abstainers who reported no alcohol consumption during the last year, (ii) 
rare drinkers, who reported no alcohol consumption for a usual two week period, but answered 
that they consumed alcohol at least once in the last 12 months and/or during the last four weeks. 
Those who reported any alcohol consumption in a usual two week period were categorised as 
(iii) consuming at most three drinks, (iv) more than three, but at most seven drinks and (v) more 
than seven drinks during a week. Daily alcohol consumption was calculated as in previous 
studies, assuming 12 g alcohol in one standard drink [3, 25, 116].  
The frequency of alcohol consumption was categorised as: (i) less than once a month, (ii) one to 
four times a month or (iii) more than once a week. 
Problem drinking (studies I-IV) was assessed by the CAGE questionnaire (the acronym stands 
for cut down, annoyed, guilty and eye-opener) [113], which is a short problem drinking 
screening instrument [117], and contains the following four items: ”Have you ever felt that you 
should cut down your alcohol intake?”; “Have other people annoyed you by ever criticizing 
your use of alcohol?”; “Have you ever felt bad or guilty because of your use of alcohol?”, 
“Have you ever had a drink first thing in the morning as a pick-me-up or to calm your nerves or 
to cure a hangover (eye-opener)?”. For all four questions, the respondents could answer either 
“yes” or “no”. According to a validation study in HUNT, at least two affirmative answers on the 
four questions have high specificity for detecting  problem drinking behaviour [118].  
Binge drinking (studies III and IV) was assessed only in HUNT3. The question: “How often do 
you drink 5 glasses or more of beer, wine or spirits in one setting” was used. Those who 
answered monthly, weekly or daily (in study III) and weekly or daily (in study IV) were 
considered binge drinkers.  
Risky drinking (studies III and IV) was defined based on a report of either binge drinking and/or 
at least two affirmatory answers on the CAGE questionnaire. 
Previous alcohol consumption and categorisation of abstainer: In study I and II information on 
previous alcohol consumption could be obtained from HUNT1 for a substantial proportion of 
HUNT2 participants. In HUNT1 participants were asked about how often they drank alcohol in 
the past two weeks. They could choose from the following answers: (i) did not drink alcohol, 
although not an abstainer, (ii) drank alcohol one or four times, (iii) drank alcohol five to 10 
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times, (iv) drank alcohol more than 10 times, or (v) abstainer. According to the answers given, 
abstainers in HUNT2 were further categorized as long-term abstainers, if they were abstainers 
or reported no alcohol consumption in HUNT1 and abstainers, who were former drinkers if 
they reported alcohol consumption at HUNT1. For Study III and IV, previous alcohol 
consumption was obtained from the HUNT2 questionnaire. Participants who gave valid 
answers to the alcohol-related questions in HUNT2 were categorised as drinkers if they reported 
at least one alcoholic drink during a regular two week period or non-drinkers if they reported no 
alcohol consumption during a regular two week period. Abstainers from HUNT3 were 
categorized similarly as (i) long-term abstainers if they were non-drinkers in HUNT2, and (ii) 
abstainers, who were former drinkers, if they reported any alcohol consumption in HUNT2.  
 Outcome information 3.2.2
In study I and II the HUNT2 population was followed for incident AMI and HF, respectively. In 
study IV the HUNT3 population was followed for incident AF. In all three studies cases were 
identified from the medical records of the two regional hospitals of Nord-Trøndelag County and 
for study I and II also from the National Cause of Death Register.  
3.2.2.1 Acute Myocardial Infarction (study I and II) 
Participants were followed for AMI until December 31
st
, 2008. To identify AMIs the diagnostic 
criteria of the European Society of Cardiology/American College of Cardiology consensus 
guideline was used [119]. The diagnoses of AMI were based on experiencing specific 
symptoms, changes in the blood level of specific enzymes and specific changes in ECG. Cases 
that did not reach the hospitals were identified from the National Cause of Death Register using 
the ICD-9 code 410 and the ICD-10 codes I21 and I22. The AMI was defined as fatal if the 
patient died within the first 28 days, and non-fatal if the patient survived the first 28
 
days. 
Previous AMI cases were identified by searching for diagnoses in the five years prior to the 
baseline measurement in the medical records as well as from the HUNT2 questionnaire with the 
question “Have you ever been diagnosed with AMI?”. 
3.2.2.2 Heart Failure (study II) 
Participants were followed for HF until December 31, 2008. The diagnoses of HF were based 
on the Guideline of the European Society of Cardiology and included symptoms and signs of 
HF and evidence of cardiac dysfunction [45]. Cases that did not reach the hospital were 
identified from the National Cause of Death Register using the ICD-9 code: 428 and the ICD-10 
codes 150.0, 150.1 and, 150.9. Previous HF cases were identified by searching for HF 
diagnoses in the 5 years prior to the baseline measurement in the hospital discharge records. 
3.2.2.3 Left ventricular functional and structural indices 
The echocardiography measurements were conducted by an experienced medical professional 
according to the American Society of Echocardiography and European Society of 
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Echocardiography recommendations [120]. The echocardiography was assessed in a left-lateral 
decubitus position using a Vivid 7 scanner (version BT06, GE Ultrasound, Horten, Norway) 
with a phased-array transducer (M3S and M4S). The echo-Doppler examination was conducted 
in the parasternal long-, short-axis views and in three standard apical views. In each orientation, 
at least three consecutive cardiac cycles were recorded and the functional indices were 
calculated using the average specific values of the three cycles. From the three apical planes, 
separate greyscale and colour tissue Doppler imaging were recorded. Systolic mitral annular 
excursions (MAE) were acquired from the base of the inferoseptal, anterolateral, inferior and 
anterior wall. Peak systolic (S’) and peak early diastolic mitral annular velocity (e’) were 
calculated as the average of the peak velocities measured at the same locations by pulsed-wave 
tissue Doppler echocardiography [120]. Tricuspid annular plane systolic excursion (TAPSE) 
and tricuspid annular peak systolic velocity (RS’) were measured close to the tricuspid plane in 
the free wall of the right ventricle. Global longitudinal end-systolic strain (the percentage of LV 
shortening during the systole) and peak global strain rate (the maximum speed of the global 
longitudinal strain) were measured as the average of the segmental values based on the 16 
segments model of the LV. Mitral inflow early (E) and late (A) diastolic velocities were 
recorded by pulse wave Doppler, and the E/A ratio was calculated.  E/e’ ratio was also 
calculated as the ratio of the peak early diastolic mitral inflow per mitral annular early diastolic 
velocities.The test-retest mean errors between two observers for these LV functional indices 
were between 4% and 9%. 
Conventional LV structural indices (interventricular septum and posterior wall thickness and 
LV internal dimensions) were assessed in parasternal M-mode. Left ventricular mass was 
estimated according to the Cube formula and was indexed for the body surface area (BSA) 
[120]. Relative wall thickness (RWT) was calculated as two times LV posterior wall thickness 
divided by the LV end-diastolic diameter. 
The EchoPAC SWO by GE Ultrasound and the GcMat software package on MatLab 
(MathWorks, Inc., Natick, MA, USA) were used for the analyses [114].  
3.2.2.4 Atrial Fibrillation (study IV) 
The HUNT3 cohort was followed until November 30
th
, 2015. AF or atrial flutter diagnoses 
(ICD10 code I48) were retrieved from the hospital diagnoses register of the two regional 
hospitals. All medical records of those who had an AF diagnosis in the register were analysed, 
and ECGs was reviewed by experienced physicians. Only cases where the ECG showed 
evidence of AF or atrial flutter according to the standard criteria [49] were considered AF. In 
doubtful cases (n=17) a cardiologist and a specialist in internal medicine reviewed the medical 
record, and the case was discussed in a consensus meeting [121]. AF cases between 1988 and 
the baseline assessment were identified from the hospital records. 
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 Covariates 3.2.3
3.2.3.1 Socio-demographic variables 
In study I-III the highest achieved education was used as an indicator for socioeconomic status 
and was categorised as (i) primary or lower secondary school (≤9 years), (ii) upper secondary 
school (>9 and ≤12 years) and (iii) high school/university (>12 years). In study IV the Erikson 
Goldthorpe Parocarero occupational group scale was used [122]. The last reported occupation 
was transformed into an Erikson Goldthorpe Parocarero group, using the categories from a 
study in HUNT2 where original Erikson Goldthorpe Parocarero categories were related to 
common occupations in the Nord-Trøndelag County [122, 123]. The occupational categories 
were further categorized as: (i) higher grade professionals, such as legislators, managers, senior 
officers, medical doctors; (ii) lower grade professionals, such as technicians, managers of small 
businesses, secretaries; (iii) routine non-manual workers, such as clerks, service workers, shop 
assistants; and (iv) manual workers, such as agricultural workers, fishery workers, machine 
operators, and construction workers. 
In study I and II marital status was categorized as (i) cohabiting and (ii) living alone. In study 
III and IV, the following categories were used: (i) never married, (ii) married or cohabiting and 
(iii) separated or widowed. 
3.2.3.2 Lifestyle factors 
Participants were classified as never, former and current smokers in study I-III and never, 
former, occasional and daily smoker in study IV. Smoking pack-years were also calculated in 
study I and II as the product of smoking duration (in years) and the average number of packets 
per day smoked during a year. 
Participants reported the level and the average duration of their physical activity. The level of 
physical activity was considered intense if it caused sweating and heavy breathing or 
breathlessness. Otherwise, it was considered light activity. In study I and II, participants were 
categorized as: (i) inactive, if they reported less than one hour intense or less than three hours 
light physical activity; (iii) moderately active, in case of one to three hours intense or more than 
three hours light physical activity; and (iii) very active, in case of more than three hours intense 
physical activity per week. In study III, a physical activity index was available for the 
echocardiography cohort, which has been shown to have a good correlation with the VO2 max 
value in a validation study [124]. In study IV, physical activity was categorized as: (i) 
physically inactive, in case of light to moderate physical activity at most 30-60 minutes per 
week, (ii) moderately active, in case of light to moderate physical activity more than 60 minutes 
a week and/or vigorous activity up to a maximum of 60 minutes a week and (iii) physically 
active, in case of vigorous activity more than 60 minutes a week. 
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3.2.3.3  Comorbidities 
Participants were asked whether they have had any of the following chronic diseases: 
hypertension, angina pectoris, diabetes mellitus, cancer, asthma, goitre, hypothyroidism, 
hyperthyroidism, ankylosing spondylitis, rheumatoid arthritis, osteoporosis, epilepsy and 
fibromyalgia.  
Anxiety and depression were assessed by the Hospital Anxiety and Depression Scale which is a 
short screening instrument to self-assess anxiety and depression symptoms [125]. It was 
developed to screen for anxiety and depression in a clinical or primary care setting. The 
questionnaire encompasses seven questions with a four-point Likert-scale and contains 
subscales for anxiety and depression [125, 126]. 
3.2.3.4 Clinical measurements 
Systolic and diastolic blood pressure was measured with Dinamap 845XT (Criticon/ GE 
Healthcare) on three consecutive occasions and the average of the second and third 
measurement was considered. Anthropometrics were measured with light clothes and without 
shoes: height and hip and waist circumference were rounded to the nearest centimetre and, 
weight was rounded to the nearest half kilogram. The waist circumference was taken 
horizontally through the umbilicus and the hip circumference was taken on the largest 
circumference of the hip. Body mass index (BMI) was calculated as weight (in kilograms) 
divided by the squared value of height (in meters).  
Blood sample was taken in a non-fasting state and the time between the last meal and 
venipuncture [113] was recorded. Within two hours the blood serum was separated at the study 
centres and refrigerated at 4°C. The samples were analysed on the same day or if it was taken 
on Friday on the following Monday at the Central Laboratory of Levanger Hospital.[113] 
Serum concentration of total serum cholesterol, HDL cholesterol and triglycerides among other 
biomarkers were analysed [113]. 
3.3 STATISTICAL ANALYSES 
 Prospective analyses (studies I, II and IV) 3.3.1
3.3.1.1 Main analyses 
The associations between alcohol consumption and the risk of AMI, HF and AF respectively 
were investigated using Cox proportional hazard models. The proportional hazard assumption 
was tested using formal tests of interaction with time, ln(time) and with ln-ln curves. We found 
no evidence against the proportionality assumption for the alcohol-related variables in any of 
the studies. If a covariate did not satisfy the proportionality assumption, we included it in the 
multivariate models as a time-dependent variable.  
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In all the three studies, the average amount of alcohol intake was modelled both as a categorical 
and as a continuous variable. To detect possible non-linear or threshold effects we tested the 
best fitting fractional polynomials in the multi-adjusted model in studies I and IV [127, 128] and 
modelled alcohol consumption with restricted cubic splines in study II [129]. 
In the base model, we adjusted for age and sex. In studies I and III, we further adjusted for 
education, marital status, smoking, physical activity and BMI. In study IV, we also included 
height and diabetes in the multi-adjusted model. 
We further analysed whether adjustment for other possible confounders, such as waist-hip ratio, 
anxiety, depression, having diabetes (studies I and II) or high blood pressure influenced the 
strength of the observed associations. In study II, we also examined to what extent AMI during 
the follow-up mediates the association between alcohol consumption and the risk of HF. 
Therefore we excluded participants with a history of AMI before the baseline measurement and 
included AMI during the follow-up as a time-dependent variable. 
To control for the sick-quitter bias, we studied the change in estimates after repeating our 
analyses after excluding abstainers who were former drinkers. In study I and II, we also 
examined the risk estimates in the different abstainer group categories. We compared the risk of 
AMI or HF for abstainers who were former drinkers, and drinkers with and without problem 
drinking to long-term abstainers. 
We investigated whether the frequency of drinking was associated with the risk of AMI and HF 
with adjusting to the amount of alcohol consumption parallel with adjusting to drinking 
frequency. We examined whether the hazard ratios (HRs) differ among drinkers with and 
without problem drinking (studies I and II). In study IV, we further adjusted our multi-variable 
model for binge drinking and examined the change in the estimates. In study IV we also 
calculated the population attributable AF risk for alcohol consumption within the recommended 
limits (i.e., ≤ seven drinks per week for women and ≤ 14 drinks per day for men without risky 
drinking) using the %par macro in SAS [130]. 
We conducted beverage-specific analyses for beer, wine and spirits by examining the effect of 
one specific beverage while simultaneously adjusting for the other two types of alcoholic 
beverages.  
3.3.1.2 Sensitivity analyses 
In study I and II, we performed analyses when we included in the outcome only AMIs or HFs 
identified from hospital records; events that appeared only in the National Cause of Death 
Registry were excluded as they are more likely to have been misclassified. We also investigated 
separately fatal and non-fatal AMI in relation to alcohol consumption.  
In all three studies, to decrease the possibility of reverse causation, we excluded events that 
occurred in the first five years of the follow-up. As participants with chronic diseases might 
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reduce their alcohol consumption, we examined the associations only among healthy 
participants without common chronic diseases. 
We performed stratified analyses to examine potential effect modification by age, sex, smoking 
and BMI.  
 Cross-sectional analyses (study III) 3.3.2
We used general linear models to investigate the association between alcohol consumption and 
the echocardiographic functional and structural indices. Least square means of the functional 
indices (MAE, global longitudinal strain, global longitudinal strain rate, peak early diastolic and 
systolic mitral annular velocities (e’, S’), E/e’, E/A, TAPSE and RS’) and of the structural 
indices (myocardial mass, wall thickness and dimensions) and 95% confidence intervals (CIs) 
were calculated across alcohol consumption categories. Apart from analysing the whole 
population, we also presented the sex-specific estimates in the main analyses as the reference 
values for most of the echocardiographic measurements are sex-specific [120, 131]. We also 
tested linear as well as quadratic trends. The multivariable model was adjusted for age, 
education, marital status, physical activity, smoking, BMI and sex (if not stratified). We further 
analysed whether including systolic blood pressure changes the estimates.  
To test for the “sick quitters” bias [132], similarly to studies I-II and IV, we repeated our main 
analyses while excluding abstainers who reported alcohol intake during the previous HUNT. 
We examined whether adding drinking frequency to the multi-adjusted model modifies the 
observed associations between the quantity of alcohol consumption and LVF. To determine 
whether risky drinking modified the observed associations, we stratified our analyses by 
reported risky drinking.  
We conducted stratified analyses by sex, age, (dichotomised at 50 years), smoking and BMI 
(dichotomised at 25 kg/m
2
) to address effect modification. 
Statistical analyses were performed using SAS Enterprise Guide 6.0 (SAS Institute) and Stata 
IC/12.1 for Windows (Stata Corp LP). 
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4 RESULTS 
4.1 QUANTITY OF ALCOHOL CONSUMPTION 
 Quantity of alcohol consumption and risk of AMI (study I) 4.1.1
There were 2 966 persons who had a first AMI during the 11.6 ± 2.5 years long follow-up 
(Figure2). The average alcohol consumption of those included in study I was 3.0 ± 4.8 g, and 
the majority of the study participants (41%) reported consumption of less than one alcoholic 
beverage over an average two week period (Table1). Drinkers were more likely to be male, 
younger, smokers and physically more active than abstainers or rare drinkers. The risk of 
AMI was lower among regular drinkers than among abstainers and rare drinkers, even after 
adjustment for several confounders (Table2).  
Table2. HRs with 95% CIs for AMI according to the weekly amount of alcohol consumed 
Groups according to 
average alcohol consumption 
No. of events/ 
person-years 
HR (95% CI) 
Base model Multi-adjusted 
model 
Abstainers and rare drinkers*  1541 / 240 713 Reference Reference 
≥0.5 and ≤2.5 drinks per week 498 / 126 867 0.93 (0.84-1.04) 0.93 (0.85-1.06) 
>2.5 and ≤5 drinks per week 373 / 152 320 0.83 (0.74-0.94) 0.78 (0.68-0.89) 
>5 and ≤7 drinks per week 96 / 30 780 0.96 (0.78-1.19) 0.86 (0.71-1.01) 
>7 drinks per week 50 / 23 232 0.68 (0.51-0.91) 0.65 (0.48-0.87) 
HR, hazard ratio; CI, confidence interval; 
The base model was adjusted for age and sex (n = 58 827). The multi-adjusted model was adjusted 
for age, sex, level of education, marital status, level of physical activity, body mass index and 
problem drinking (n = 55 710).  
*Consuming less than one drink in an average two week period. 
When we modelled alcohol consumption as a continuous variable, the best fitted fractional 
polynomial model showed a linear association between daily average alcohol intake and AMI 
risk. In the linear model, one drink increment of alcohol consumption was associated with a 
28% lower AMI risk (adjusted HR 0.72, 95% CI 0.62–0.86) (Figure4). Additional adjustment 
for anxiety, depression, diabetes and blood pressure resulted in similar estimates. When we 
compared fatal and non-fatal AMI, the association was stronger in non-fatal AMI (multi-
adjusted HR 0.67, 95% CI: 0.54-0.80) than for fatal AMI (multi-adjusted HR was 0.86, 95% 
CI: 0.64-1.15). 
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Table1. Baseline characteristics of the HUNT2 participants, free from history of AMI or HF at baseline, according to alcohol consumption (study I, II) 
BMI: body mass index; BP: blood pressure; HDL-C: high-density lipoprotein cholesterol; Blood pressure was measure in mmHg, and HDL-C in mmol/L. Anxiety and Depression 
was measured by the Hospital Anxiety and Depression Scale. *Problem drinkers, defined as at least two affirmatory answers in the CAGE questionnaire. 
Study 
Variables 
No. of participants Alcohol consumption categories 
 <0.5 drinks  
week
-1 
≥0.5 and ≤2.5 drinks 
week
-1
 
>2.5 and ≤5 drinks 
week
-1
 
>5 and ≤7 drinks  
week
-1
 
>7 drinks  
week
-1
 
 Study I Study II Study I Study II Study I Study II Study I Study II Study I Study II Study I Study II 
Categorical variables, %(n) 
Total 58 827 60 665 41(23 942) 41(25 043) 26(15 246) 26(15 619) 24(14 368) 24(14 661) 5(2 977) 5(3 028) 4(2 276) 4(2 314) 
Sex(male) 46(27 086) 47(28 422) 33(7 996) 33(8 697) 43(6 614) 44(6 905) 58(8 338) 59(8 600) 74(2 214) 75(2 262) 85 (1 924) 85(1 958) 
Smoking 
Current 29(16 910) 29(17 339) 23(5 385) 22(5 608) 29(4 453) 29(4 543) 34(4 928) 34(5 015) 40(1 179) 40(1 199) 42(965) 42(974) 
Former 24(14 290) 25(15 214) 22(5 131) 23(5 619) 25(3 840) 26(4 048) 27(3 916) 28(4 091) 28(821) 28(849) 26(582) 26(606) 
Never 47(27 581) 46(28 063) 56(13 387) 55(13 775) 46(6 965) 45(7 021) 38(5 523) 38(5 553) 33(977) 32(980) 32(729) 32(734) 
Physical activity level 
Inactive  57(33 275) 70(34 449) 65(15 524) 65(16 299) 54(8 257) 54(8 465) 49(7 063) 49(7 210) 46(1 367) 46(1 396) 47(1 064) 47(1  079) 
Moderate 34(20 208) 21(20 779) 29(7 037) 29(7 318) 37(5 570) 37(5 698) 39(5 631) 39(5 757) 39(1 145) 39(1 165) 36(825) 36(841) 
Very active 9(5 344) 10(5 437) 6(1 381) 6(1 426) 9(1 437) 9(1 456) 12(1 674) 12(1 694) 16(465) 15(467) 17(387) 17(394) 
Living alone 40(23 451) 40(24 018) 39(9 364) 39(9 800) 36(5 457) 36(5 531) 41(5 871) 41(5 943) 47(1 393) 47(1 405) 59(1 330) 58(1 339) 
Education 
≤9 years 35(19 802) 36(20 843) 51(11 281) 52(11 975) 28(4 206) 29(4 392) 23(3 323) 24(3 462) 20(583) 20(597) 18(409) 18(417) 
10-12 years 44(24 870) 44(25 325) 34(7 691) 34(7 888) 48 (7 232) 48(7 348) 51(7 181) 50(7 280) 53(1 546) 53(1 572) 54(1 220) 54(1 237) 
>12 years 21(11 760) 21(11 915) 14(3 147) 14(3 206) 23 (3 502) 23(3 537) 26(3 679) 26(3 718) 28(809) 27(819) 28(623) 28(635) 
Problemdr* 5.4(3 158) 5.3(3 211) 0.5(288) 0.5(295) 2.9(441) 2.9(456) 9.0(1 296) 9.0(1 313) 17.5(521) 17.4(528) 27(612) 27(619) 
Continuous variables, mean (SD) 
Age 49.1(16.9) 49.7(17.1) 56.2(17.6) 56.9(17.6) 45.6(14.9) 46.1(15.1) 43.5(13.9) 43.9(14.1) 42.9(14.5) 43.2(14.6) 41.2(15.2) 41.6(15.4) 
BMI 26.3(4.1) 26.3(4.1) 26.9(4.5) 26.9(4.5) 26.0(3.9) 26.0(3.9) 25.9(3.6) 25.9(3.6) 26.0(3.6) 26.0(3.6) 26.0(3.5) 26.1(3.5) 
Anxiety 4.3(3.3) 4.2(3.3) 4.3(3.5) 4.2(3.5) 4.2(3.2) 4.2(3.2) 4.2(3.2) 4.2(3.2) 4.3(3.2) 4.3(3.2) 4.5(3.5) 4.5(3.5) 
Depression 3.4(3.1) 3.5(3.1) 3.8(3.3) 3.9(3.3) 3.2(2.9) 3.2(2.9) 3.1(2.8) 3.1(2.8) 3.2(2.9) 3.2(2.9) 3.4(3.0) 3.4(3.0) 
Systolic BP  137(22) 138(21) 142(24) 142(24) 133(20) 134(20) 133(18) 133(18) 135(18) 135(18) 136(17) 136(17) 
Diastolic BP 81(12) 80(12) 81(13) 81(13) 79(12) 79(12) 79(12) 79(12) 80(12) 80(12) 80(12) 80(12) 
HDL-C 1.39 (0.39) 1.38 (0.39) 1.37(0.38) 1.36(0.38) 1.40(0.39) 1.39(0.39) 1.39(0.39) 1.39(0.39) 1.38(0.39) 1.38(0.39) 1.38(0.39) 1.38(0.40) 
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Figure 4. Multi-adjusted HRs with 95% CIs for AMI according to daily alcohol intake 
 
 
 Quantity of alcohol consumption and risk of HF (study II) 4.1.2
During the 11.2 ± 3.0 years long follow-up 1 588 first HF cases were identified, 1 134 from 
the hospital records and 454 exclusively from the cause of death register (Figure 2). Table 3 
shows the multi-adjusted HRs for HF according to alcohol consumption categories. The risk 
of HF was lower among drinkers compared to non-drinkers (Table 3). 
Table 3. HRs with 95% CIs for HF according to the weekly amount of alcohol consumed 
Groups according to 
average alcohol consumption 
No. of events/ 
person-years 
HR (95% CI) 
Base model Multi-adjusted 
model 
Abstainers and rare drinkers*  1158/ 270 942 Reference Reference 
≥0.5 and ≤2.5 drinks per week 235 /181 250 0.88 (0.77-0.99) 0.85 (0.73-0.99) 
>2.5 and ≤5 drinks per week 138 / 169 067 0.76 (0.63-0.91) 0.72 (0.60-0.88) 
>5 and ≤7 drinks per week 34 / 34 237 0.87 (0.62-1.23) 0.89 (0.62-1.27) 
>7 drinks per week 23 / 25 636 0.80 (0.53-1.24) 0.82 (0.54-1.25) 
HR, hazard ratio; CI, confidence interval; 
The base model was adjusted for age and sex (n = 60, 665). The multi-adjusted model was adjusted 
for age, sex, level of education, marital status, level of physical activity, body mass index and 
problem drinking (n = 57 318).  
*Consuming less than one drink in an average two week period. 
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Adding waist-hip ratio, anxiety or depression to the multi-adjusted model did not alter the 
association between alcohol consumption and HF substantially. The continuous model 
showed a non-linear association (p<0.001) (Figure 5).  
Figure 5 Multi-adjusted HRs with 95% CIs for HF according to daily alcohol consumption 
 
 Quantity of alcohol consumption and LV function (study III) 4.1.3
The majority of the study participants in study III were light drinkers, consuming less than 
three drinks per week; only 4.5% of the participants reported more than seven alcoholic 
drinks per week (Table 4). Table 5 shows the association between the quantity of alcohol 
intake and LV indices, which were largely similar across the different alcohol intake 
categories. LV mass and LV end diastolic dimension were positively associated with alcohol 
consumption (Table 6). 
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Table 4. Baseline characteristics of the study participants according to alcohol consumption (study III) 
Study variables No. of participants Alcohol consumption categories 
<0.5 drinker week
-1*  ≥0.5 and ≤3 drinker 
week
-1
 
>3 and ≤7 drinker 
week
-1
 
>7 drinker week
-1
 
 Women Men Women Men Women Men Women Men Women Men 
Total 613 566 98 86 364 344 123 110 28 26 
Categorical variables, n(%) 
Education 
   Primary-Secondary 86(400) 67(376) 64(61) 75(63) 66(244) 68(234) 67(81) 61(66) 50(14) 50(13) 
   Tertiary 24(205) 33(187) 36(34) 26(22) 33(117) 32(109) 33(40) 40(43) 50(14) 50(13) 
Smoking 
   Never-former 77 (451) 74 (435) 83 (46) 76 (70) 74 (451) 78 (266) 70 (86)  75 (83) 64 (18) 62 (16) 
   Current 23 (153) 26 (126) 17 (23) 24 (14) 26 (84) 22 (75) 30 (36) 25 (27) 36 (10) 38 (10) 
Marital status  
   Living alone 41 (249) 36 (203) 47 (46) 36 (47) 39 (142) 33 (115) 40 (49) 39 (43) 43 (13) 54 (14) 
   Cohabiting, married 59 (363) 64 (362) 53 (52) 64 (55) 61 (222) 67 (228) 60 (73) 61 (67) 57 (16) 46 (12) 
Continuous variables, mean (SD) 
Age (years) 49.3(13.6) 49.0(13.5) 49.1(14.9) 51.4(15.5) 49.2(13.7) 49.0(13.0) 49.6(13.2) 48.4(13.1) 49.6(11.7) 44.0(12.7) 
Body mass index (kg/m
2
) 26.3 (4.0) 26.3 (3.7) 27.3 (4.9) 27.3 (4.6) 26.1 (3.9) 26.1 (3.7) 26.2 (3.7) 26.2 (3.3) 25.9 (2.4) 25.9 (2.9) 
Physical activity index 2.1 (0.8) 2.2 (0.8) 2.0 (0.8) 2.1 (0.7) 2.2 (0.8) 2.1 (0.8) 2.0 (0.9) 2.2 (0.8) 2.1 (0.8) 2.2 (0.8) 
Systolic blood pressure 127 (17) 133 (14) 127 (17) 132 (15) 127 (17) 133 (14) 126 (16) 133(14) 130 (25) 133 (12) 
Diastolic blood pressure  71 (10) 77 (10) 70 (9.6) 77 (10) 71 (10) 77 (10) 73 (10) 77 (10) 75 (13) 74 (8) 
*
Reported consuming less than one alcoholic drink consumption in a regular two week period. Blood pressure was measured in Hgmm 
 
Table 5. Least square means and 95% CIs for LV functional indices according to the weekly amount of alcohol consumed 
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 N Least square means* (95% CI) of alcohol consumption categories P-values 
  Non-drinkers ≥0.5 and ≤3 drinks week-1 >3 and ≤7drinks week-1 >7 drinks week-1 Linear Quadratic 
Mitral Annular Excursion (cm) 
Men 534 1.57 (1.51, 1.63) 1.57 (1.54, 1.61) 1.59 (1.54, 1.64) 1.64 (1.55, 1.74) 0.18 0.37 
Women 544 1.57 (1.52, 1.63) 1.59 (1.56, 1.63) 1.61 (1.56, 1.66) 1.57 (1.47, 1.67) 0.98 0.34 
Global longitudinal strain (%) 
Men  548 -15.9 (-16.4,-15.3) -16.0 (-16.2,-15.7) -16.0 -(16.2,-15.5) -16.2 (-17.1,-15.2) 0.70 0.59 
Women 587 -17.7 (-18.2,-17.3) -17.4 (-17.6,-17.1) -17.3 (-17.7,-16.8) -17.1 (-17.9,-16.2) 0.34 0.42 
Global longitudinal strain rate (s
-1
) 
Men  513 -1.01 (-1.04,-0.98) -1.04 (-1.06,-1.03) -1.04 (-1.07,-1.02) -1.00 (-1.06,-0.95) 0.74 0.05 
Women 548 -1.02 (-1.05,-0.99) -1.02 (-1.03,-1.00) -1.04 (-1.06,-1.01) -1.04 (-1.09,0.99) 0.34 0.89 
Peak early diastolic mitral annular velocity (e’) (cm/s) 
Men  528 11.1 (10.4, 11.7) 10.6 (10.3, 10.9) 11.1 (10.6, 11.7) 11.6 (10.4, 12.9) 0.40 0.44 
Women 556 11.6 (11.0, 12.2) 11.6 (11.3, 11.9) 12.2 (11.6, 12.7) 11.5 (11.4, 13.5) 0.10 0.67 
Peak systolic mitral annular velocity (S’) (cm/s) 
Men  520 8.72 (8.38, 9.05) 8.63 (8.44, 8.83) 8.83 (8.54, 9.11) 9.07 (8.51, 9.63) 0.30 0.87 
Women 556 8.13 (7.86, 8.40) 8.27 (8.10, 8.43) 8.20 (7.95, 8.45) 8.20 (7.71, 8.69) 0.69 0.85 
E/A ratio 
Men  552 1.41 (1.29, 1.53) 1.38 (1.31, 1.45) 1.42 (1.32, 1.53) 1.31 (1.11, 1.50) 0.48 0.49 
Women 586 1.37 (1.28, 1.46) 1.36 (1.30, 1.41) 1.34 (1.36, 1.42) 1.31 (1.14, 1.47) 0.41 0.90 
E/e’ ratio  
Men  545 6.92 (6.24, 7.59) 7.24 (6.86, 7.63) 6.83 (6.26, 7.40) 6.81 (5.71, 7.92) 0.74 0.60 
Women 580 6.52 (5.96, 7.01) 6.67 (6.33, 7.00) 6.27 (5.76, 6.79) 6.34 (5.33, 7.34) 0.61 0.99 
Peak tricuspid annular systolic velocity (RS’) (cm/s) 
Men  549 12.9 (11.9, 12.7) 12.8 (12.3, 12.8) 13.0 (12.2, 13.0) 13.0 (11.8, 13.2) 0.76 0.91 
Women 587 12.3 (12.4, 13.4) 12.5 (12.5, 13.0) 12.6 (12.6, 13.4) 12.5 (12.1, 13.8) 0.57 0.39 
Tricuspid annular plane systolic excursion (TAPSE) (cm) 
Men  570 2.80 (2.66, 2.94) 2.85 (2.78, 2.92) 2.94 (2.82, 3.06) 2.84 (2.61, 3.08) 0.91 0.31 
Women 527 2.72 (2.62, 2.83) 2.81 (2.75, 2.87) 2.78 (2.69, 2.88) 2.74 (2.55, 2.93) 0.59 0.33 
*Means are adjusted for age, marital status and education, smoking, physical activity and body mass index. 
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Table 6. Least square means and 95% CIs for LV structural indices according to the weekly amount of alcohol consumed 
 N Least square means* (95% CI) of alcohol consumption categories (drinks per week) P-values 
  Non-drinkers ≥0.5 and ≤3 drinks 
week
-1 
>3 and ≤7drinks  
week
-1
 
>7 drinks  
week
-1
 
Linear Quadratic 
LV mass (gr) 
Men  551 157.0 (146.8 - 167.2) 158.6 (153.1 - 164.0) 169.5 (160.7 - 178.2) 182.1 (164.6 - 199.7) <0.01 0.92 
Women 578 151.6 (142.0 - 161.2) 159.5 (154.1 - 164.9) 169.3 (160.6 - 177.9) 180.0 (162.7 - 197.3) <0.01 0.13 
LV mass per body surface area (gr/m
2
) 
Men  550 76.8 (71.5 - 82.1) 78.6 (75.8 - 81.4) 83.0 (78.5 - 87.5) 91.4 (82.3 - 100.4) <0.01 0.67 
Women 577 86.1 (80.4 - 91.8) 90.4 (87.2 - 93.6) 95.5 (90.4 -  100.6) 102.6 (92.4 - 112.8) <0.01 0.02 
LV end diastolic diameter (mm) 
Men  548 50.7 (49.5 - 51.9) 50.9 (50.3 - 51.5) 51.0 (50.0 - 52.0) 52.1 (50.0 - 54.2) 0.03 0.23 
Women 577 49.4 (48.3 - 50.5) 50.4 (49.8 - 51.1) 51.4 (50.4 - 52.4) 52.5 (50.5 - 54.6) 0.07 0.31 
LV end systolic diameter (mm) 
Men  548 32.3 (31.2 - 33.4) 32.4 (31.8 - 33.0) 32.4 (31.5 - 33.4) 33.9 (31.9 - 35.8) 0.17 0.29 
Women 577 31.1 (30.1 - 32.1) 32.2(31.6 - 32.8) 32.7 (31.8 - 33.7) 34.6 (32.8 - 36.5) <0.01 0.48 
Relative wall thickness (cm) 
Men  551 0.25 (0.24 - 0.26) 0.26 (0.25 - 0.26) 0.27 (0.27 - 0.27) 0.27 (0.25 - 0.28) 0.07 0.96 
Women 578 0.26 (0.25 - 0.27) 0.26 (0.26 - 0.27) 0.26 (0.26 - 0.27) 0.27 (0.26 - 0.28) 0.47 0.31 
*Adjusted for age, marital status, education, smoking, physical activity and body mass index 
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 Quantity of alcohol consumption and risk of AF (study IV) 4.1.4
Overall, 23% of participants included in Study IV reported intake of more than three drinks 
per week and the average alcohol consumption in the population was 3.8 ± 4.8 g (Table7). 
Alcohol consumption was associated with an increased risk of AF over seven drinks per week 
intake when compared to non-drinkers (Table 8). The risk of AF was similar among non-
drinkers, rare drinkers and light drinkers. Further adjustment for waist-hip ratio, anxiety, 
depression, or blood pressure did not change the estimates considerably. We also modelled 
alcohol consumption as a continuous variable in a linear model, where the HR for a one-drink 
increment was 1.03 [95% CI: 1.01-1.04]. The best fitting fractional polynomial indicated a 
curvilinear association instead of a truly linear one (Figure 6). 
  
  31 
Table7: Baseline characteristics of the HUNT3 participants, free from a history of AF at 
baseline, according to alcohol consumption (study IV) 
Study variables No. of 
participants 
 
Alcohol intake categories (drinks week
-1
)
 
Abstainers Rare-
drinkers* 
>0 and ≤3 >3 and ≤7 >7 drinks 
week
-1
 
Total 47 002 5 302 6 212 24 792 8 391 2 305 
Categorical variables, % (n) 
Sex (female) 55 (25 885) 70 (3 719) 69 (4 271) 57 (14 216) 37 (3 143) 23 (536) 
Physical activity  
Inactive 22 (10 100) 26 (1 327) 25 (1 525) 20 (4 959) 21 (1 727) 24 (562) 
Moderate 42 (19 562) 52 (2 624) 45 (2 7849) 42 (10 282) 37 (3 098) 34 (774) 
Active 36 (16 808) 22 (1 083) 30 (1 832) 38 (9 389) 42 (3 545) 42 (959) 
Smoking 
Current 25 (11 415) 16 (830) 22 (1 383) 24 (5 902) 30 (2 512) 35 (788) 
Former  34 (14 850) 25 (1 273) 28 (1 707) 33 (7 983) 36 (3 012) 38 (875) 
Never  42 (19 910) 59 (2 986) 49 (2 993) 43 (10 534) 33 (2 780) 27 (617) 
Living in a 
relationship 
24 (11 128) 17 (891) 26 (1 616) 23 (5 639) 26 (2 188) 35 (794) 
Binge drinker** 3 (1 552) 0 (0) 0 (0) 1 (152) 7 (582) 35 (818) 
Problem drinker|§ 9 (3 001) 3 (40) 3 (101) 5 (1 035) 17 (1 157) 39 (668) 
Previous CVD†  9 (4 414) 17 (925) 11 (691) 8 (2 039) 7 (582) 8 (177) 
Chronic disease# 69 (24 929) 59 (3 692) 59 (3 678) 50 (12 518) 47 (3 947) 48 (1 094) 
Continuous variables, mean (SD) 
Age, years (n=47,002) 52.3 (15.7) 62.3(16.8) 53.5(17.2) 51.2 (14.6) 49.5 (14.0) 47.6 (15.5) 
BMI, kg/m
2
(n=46,683) 27.1 (4.4) 27.7 (4.9) 27.7 (5.0) 27.0 (4.3) 26.9 (3.9) 26.8 (3.9) 
HDL-C (n=45,677) 1.3 (0.35) 1.3 (0.3) 1.3 (0.3) 1.4 (0.3) 1.4 (0.4) 1.3 (0.4) 
Systolic BP (n=46,739) 130 (19) 135 (21) 130 (20) 129 (18) 131 (17) 133 (17) 
Diastolic BP (n=46,739) 73 (11) 73 (12) 72 (11) 73 (11) 75 (11) 75 (12) 
Anxiety (n=36,563) 4.01 (3.3) 4.2 (3.7) 4.2 (3.6) 4.0 (3.2) 3.9 (3.2) 4.0 (3.3) 
Depression (n=36,777) 3.3 (2.9) 3.9 (3.2) 3.6 (3.1) 3.1 (2.8) 3.0 (2.7) 3.3 (2.9) 
SD: standard deviation; CVD: cardiovascular diseases; BMI: body mass index; HDL-C: high density 
lipoprotein cholesterol, measured in mmolL
-1
; BP: blood pressure, measured in Hgmm 
*Defined as reporting consuming alcohol during the last year, but not during the past two weeks. 
**Binge drinkers were defined as drinking ≥ 5 drinks in one setting at least once a week. 
§Defined as has at least two affirmatory answers in the CAGE questionnaire. 
†Defined as ever having acute myocardial infarction, angina pectoris, heart failure, other heart disease and/or 
stroke/brain haemorrhage. 
#Defined as ever having any of the following: hypertension, diabetes, angina pectoris, heart failure, other 
heart disease, stroke/brain haemorrhage, kidney disease, asthma, chronic bronchitis, emphysema, chronic 
obstructive pulmonary disease, cancer, epilepsy, rheumatoid arthritis, Bechterev’s disease, sarcoidosis or 
osteoarthritis. 
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Table 8. HRs with 95% CIs for AF according to the weekly amount of alcohol consumed 
Groups according to 
average alcohol 
consumption 
No. of events/ 
Person years 
HR (95% CI) 
Base model Multi-adjusted 
model* 
Abstainers 347/ 41,694 Reference Reference 
Rare-drinkers† 258/ 50,411 1.03 (0.88-1.21) 1.04 (0.88-1.24) 
>0 and ≤3 drinks per week 725/ 205,234 0.94 (0.82-1.08) 1.00 (0.87-1.63) 
>3 and ≤7 drinks per week 225/ 68,994 1.00 (0.83-1.19) 1.05 (0.87-1.28) 
>7  drinks per week
 
77/ 18,434 1.25 (0.97-1.62) 1.38 (1.06-1.80) 
HR: hazard ratio; CI: confidence interval.  
*The base model was adjusted for age and sex (n= 47 002).The multi-adjusted model was adjusted 
for age, sex, height, body-mass index, marital status, socio-economic position, exercise, smoking, 
binge drinking and diabetes (n=45 193). 
† Rare drinkers were defined as those who reported alcohol consumption during the last year, but 
not during the last two weeks. 
Figure 6. Multi-adjusted HRs with 95% CIs for AF according to weekly alcohol consumption  
 
The cut-point where the risk deviated from the null occurred at around four-five drinks per 
week consumption. The predicted HR at an intake of four drinks per week was 1.02 (95% CI: 
1.01-1.03) and 1.08 (95% CI: 1.03-1.15) for seven drinks increment. The AF incidence 
attributable to alcohol consumption was 1.6% (95% CI: 0.6%-2.7%) when any drinkers were 
compared to non-drinkers. 
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4.2 THE EFFECT OF FORMER DRINKING  
The majority of abstainers in HUNT2 had information on their alcohol consumption in 
HUNT1 (Figure 2). When we compared the risk of AMI and HF of abstainers who were 
previous drinkers with that of long-term abstainers (n=341 in study I and n=373 in study II), 
we found that former drinkers had a slightly higher risk of both AMI (adjusted HR was 1.29, 
95% CI: 0.75-1.70) and HF (multi-adjusted HR was 1.33, 95% CI: 0.87-2.12). However, 
when we excluded abstainers who were former drinkers from the analyses the estimates 
remained mostly the same. 
In study III and IV, we used information on previous alcohol consumption from the HUNT2 
(Figure 3). Excluding abstainers who were former drinkers (n=117 in study III and n=447 in 
study IV) did not influence the association of alcohol consumption with LV function or with 
risk of AF. 
4.3 THE ROLE OF PROBLEM DRINKING (STUDIES I-II) AND RISKY DRINKING 
(STUDIES III-IV) 
In study I and II, we compared the risk of AMI and HF between drinkers regarding problem 
drinking (had at least two affirmatory answers on the CAGE questionnaire). We found that 
problem drinkers had a similar risk of AMI as drinkers without problem drinking. The multi-
adjusted HR for AMI in drinkers without problem drinking was 0.79 (95% CI: 0.69-0.90), 
and for drinkers with problem drinking was 0.81 (95% CI: 0.62-1.06) when compared to 
long-term abstainers. However, the risk of HF tended to be higher among drinkers with 
problem drinking (multi-adjusted HR: 1.27, 95% CI: 0.38-4.26) than drinkers without 
problem drinking (multi-adjusted HR was 0.80, 95% CI: 0.68-0.95) when compared to long-
term abstainers as the reference group.  
In Study III, we stratified our analyses by risky and non-risky drinkers and found that the 
means of the LV functional indices in different alcohol consumption categories did not differ 
between risky and non-risky drinkers. Similarly, there was no association between the 
amount of alcohol intake and LV functional indices in any of the groups. The positive 
association between alcohol intake and LV mass indices was stronger among risky than 
among non-risky drinkers. The multi-adjusted mean of the body surface area indexed LV 
mass for those who reported more than three but at most seven drinks per week was 82 g 
(95% CI: 77-88 g) among non-risky drinkers and 93 g (95% CI: 89-98 g) among risky 
drinkers, respectively.  
In study IV, adjusting for binge drinking did not change the estimates essentially. However, 
the attributable proportion for alcohol consumption within the recommended limits (i.e. ≤7 
drinks per week for women and ≤14 drinks per week for men, and in the absence of risky 
drinking), when compared to non-drinkers was only 0.07% (95% CI:-0.01%, 0.13%). 
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4.4 FREQUENCY OF DRINKING (STUDIES I-IV) 
We found that higher drinking frequency was associated with a lower risk of AMI and HF, 
respectively independently of the quantity of alcohol intake. The adjusted HRs for AMI were 
0.93 (95% CI 0.83-1.04) for intakes of one to four, 0.78 (95% CI 0.63-0.97) for five to 12, 
and 0.76 (95% CI 0.50-1.16) for more than 12 times per month. For HF risk the HRs was 
0.98 (95%: 0.56-1.11 ) for those who reported drinking one to four and 0.79 (95% CI: 0.83-
1.16) for those who reported alcohol intake five times or more when compared to those who 
reported drinking less than once in a month. The estimates did not differ according to 
drinking frequency in study III and IV. 
4.5 BEVERAGE SPECIFIC ANALYSES (STUDIES I-IV) 
When we investigated the effect of the different beverages types, we found similar estimates. 
However, beer consumption was associated with a slightly lower risk of AMI than wine or 
spirit consumption. The adjusted HRs were 0.76 (95% CI: 0.63-0.91) for beer and 0.68 (95% 
CI: 0.56-0.82) for wine and for spirit consumption.  
4.6 MEDIATION BY AMI (STUDY II)  
A total of 1 712 AMI cases were detected before the follow-up and 3 171 during the follow-
up in study II. Among those who had HF during the follow-up, 349 participants had AMI 
before the baseline and 133 AMI cases occurred during the follow-up period. When we 
excluded participants with a history of AMI before the baseline and adjusted for AMI during 
the follow-up as a time-dependent variable in our multi-adjusted model, we observed a slight 
change of the estimate. The multi-adjusted HR comparing participants drinking more than 
two drinks to those who reported alcohol consumption up to two drinks per week increased to 
0.84 (95% CI: 0.65-1.09) from 0.79 (95% CI: 0.62-0.98).  
4.7 EFFECT MODIFICATION AND SENSITIVITY ANALYSES (STUDIES I, II 
AND IV) 
We did not find evidence for effect modification by age, sex, exercise, smoking BMI or high 
blood pressure in any of the studies.  
When we restricted our analyses to events diagnosed in hospitals (n=1 947 AMI cases and 
n=1 134 HF cases) the strength of the association remained the same for AMI (the multi-
adjusted HR was 0.74, 95% CI: 0.62-0.88) and there was a slight reduction in the relative risk 
for HF (multi-adjusted HRs 0.85, 95% CI: 0.67-1.11). 
Excluding participants with any of the following chronic conditions; as hypertension, stroke, 
angina pectoris, diabetes mellitus, cancer, asthma, goitre, hypothyroidism, hyperthyroidism, 
ankylosing spondylitis, rheumatoid arthritis, osteoarthritis, epilepsy or fibromyalgia from the 
analyses did not considerably influence the association between alcohol consumption and risk 
of AMI, HF or AF. 
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The exclusion of the first five years of the follow-up did not weaken the associations between 
alcohol intake and AMI and HF. For AF, the risk the estimate was slightly lower after 
excluding the first four years of the follow up. The adjusted HR, – when comparing 
participants who reported consuming more than seven drinks per week to participants who 
reported up to this amount, – was 1.28 (95% CI: 1.05-1.53).  
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5 DISCUSSION 
5.1 SUMMARY OF MAIN FINDINGS  
Light to moderate alcohol intake was associated with a lower risk of AMI and HF, and 
slightly increased risk of AF over seven drinks per week of average alcohol intake. We found 
no evidence for an association between LV function and light to moderate alcohol 
consumption. The associations did not change substantially after excluding abstainers, who 
reported consuming alcohol in the previous phases of the HUNT study, and it persisted also 
after extensive adjustments for sociodemographic, psychosocial and lifestyle factors and the 
presence of common chronic disorders. Frequent, low level of alcohol consumption was 
associated with a lower AMI and HF risk than less frequent intake. Furthermore, drinking 
within the recommended limit, i.e. up to seven drinks per week for women and up to 14 
drinks per week for men without binge and/or problem drinking was not associated with an 
increased risk of AF. Drinkers with problem drinking had a lower risk of AMI, but slightly 
higher risk of HF than abstainers. However, the statistical power to investigate the latter 
association was very limited. Among risky drinkers, even if the average alcohol intake 
remained within the recommended levels the quantity of alcohol consumption was positively 
associated with LV mass indices.  
5.2 COMPARISON WITH PREVIOUS STUDIES 
 Quantity of alcohol consumption and risk of AMI, HF and AF 5.2.1
5.2.1.1 Acute myocardial infarction (study I) 
Our finding, that alcohol consumption was inversely associated with the risk of AMI, is in 
line with the majority of the previous studies in this field [24, 26]. In this low drinking 
population, where the average alcohol consumption was only 3.0±4.8 g per day, we observed 
a linear reduction of AMI risk with increasing alcohol intake. However, we could not draw 
inference on higher alcohol intake categories as excessive consumption was limited in this 
population. Only 2.8% of the study participants reported an alcohol intake of more than seven 
drinks per week. The most up-to-date meta-analysis showed maximal protection was afforded 
against IHD when consuming one to two drinks per day of average alcohol intake among 
women and one to four drinks per day of average alcohol intake among men when compared 
to abstainers [24, 26, 29]. Excluding abstainers, who were former drinkers in our study, had 
no considerable effect on the estimates, suggesting that the association was not driven by 
sick-quitters. This corroborates the findings of the earlier studies that could either separate 
abstainers who were former drinkers from long-term abstainers [24, 105] or investigated this 
question in a young adult population [133].  
5.2.1.2 Heart failure and left ventricular function (study II, III) 
A recently published meta-analysis [15], which has already incorporated the results of our 
study II, concluded that relative to abstainers light alcohol consumption (up to 7 drinks per 
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week) was associated with an approximately 14% lower risk of HF. Moderate drinkers (7-14 
drinks per week) had on average a 10% lower risk of HF. Some studies, including our, could 
separate abstainers who were former drinkers from long-term abstainers, and their meta-
analyses showed that abstainers who were former drinkers had a higher HF risk than long-
term abstainers. Furthermore, we confirmed that the inverse association between alcohol 
intake and HF persisted even when former drinkers were excluded.  
In study III, we examined the association between light to moderate alcohol consumption and 
LV function among healthy individuals, but we found no clear evidence that light to 
moderate alcohol intake would be associated with a better LV function. In a recent 
population-based study [58], decreased left ventricular ejection fraction was inversely 
associated with alcohol intake. The lowest risk for modest ejection fraction impairment was 
found among those who consumed at most one alcoholic drink per day. Another study, which 
was conducted in an elderly population and used sensitive echocardiography similar to that 
used in our study, did not find any clear association between light to moderate alcohol 
consumption and LV function [64]. While the authors described an inverse, but clinically 
irrelevant association between alcohol intake and LV ejection fraction among women, they 
found no association between moderate alcohol intake and LV functional characteristics 
among men. Lastly, a Chinese study in a middle-aged population demonstrated a worse LV 
function among those who consumed over six drinks per week than among non-drinkers 
[134]. However, it should be mentioned that many individuals with an East Asian origin have 
a slower metabolism than individuals with a Caucasian origin. This results in a longer stay of 
acetaldehyde, the cardiotoxic metabolite of alcohol, in the bloodstream [135, 136]. It may 
explain the discrepancy in results between our and other studies conducted in mainly 
Caucasian populations and the Chinese-study [64]. 
5.2.1.3 Atrial fibrillation (study IV) 
The majority of the previous studies reported an association between alcohol intake and 
increased AF risk, with an approximately 8% risk increase for a one drink increment [7, 26, 
31, 32, 69, 70, 137]. We also found an increased risk of AF with increasing alcohol 
consumption, with around a 3% risk increase for a one drink increment in the linear model. 
However, our categorical analyses suggested that the risk increase became important only 
above seven alcoholic drinks per week. When alcohol consumption was modelled as a 
continuous variable with fractional polynomials, the risk function showed a somewhat 
curvilinear shape with the first slight increase around 4 to 5 drinks per week and a steep 
increase over 14 alcoholic drinks. The previous meta-analyses in this field could not conclude 
whether the risk increase is truly linear [7, 70] or it is more threshold like [31]. Our results 
support the later, i.e. that AF risk may not increase considerably up to seven alcoholic drinks 
per week. Excluding former drinkers did not influence the association.  
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 Drinking frequency, binge- and problem drinking and risk of AMI, HF 5.2.2
and AF 
There is increasing evidence suggesting that more frequent alcohol intake within the same 
amount of consumption may be associated with more favourable health outcomes [10, 28, 29, 
74, 81, 138]. Our findings corroborate those of previous studies showing that those who 
frequently consume alcohol have the lowest risk of AMI, while occasional heavy alcohol 
intake is associated with the least favourable AMI risk even within moderate consumption 
[10, 28, 29]. Binge drinking has earlier been shown to eliminate the protective association 
between alcohol consumption and CVD [28, 29, 139-141]. Binge drinking may trigger AMI 
through an acute increase in sympathetic and thrombotic activity [28, 29, 75, 76, 142]. 
Though we had no direct information on binge drinking in studies I and II, problem drinking 
was measured by the CAGE questionnaire. Those who gave two affirmative answers on the 
questionnaire were more likely to have unhealthy drinking habits and, to be regular binge 
drinkers than those with no or one positive answer on CAGE [118]. In study I, we did not 
find considerable differences in AMI risk between drinkers with and without problem 
drinking behaviour. In contrast, in study II, alcohol intake was not associated with a lower 
risk of HF among drinkers with problem drinking compared to abstainers. This finding is in 
line with studies that found an increased risk of HF among binge drinkers compared to 
abstainers [14-16]. Furthermore, within the same amount of alcohol intake, more frequent 
drinking was associated with a lower risk of HF, than less frequent drinking. Our results seem 
to support that a pattern similar to that observed for IHD also exists for HF. Frequent low-
level alcohol consumption seems to have the most favourable association both with AMI and 
HF [74].  
As binge drinking was assessed explicitly in HUNT3, we could examine the effect of binge 
and/or problem drinking in studies III and IV. In study III, we found that among risky 
drinkers the quantity of alcohol consumption was associated with worsening values of LV 
structural indices. No similar association was found among individuals without risky 
drinking. We observed a very slight, but clinically irrelevant trend toward a better LV 
function in the latter group. Experimental studies suggest that binge drinking may trigger an 
inflammatory response in the myocytes, and may increase the susceptibility to ischemic 
injury [79]. Binge drinking may also induce myocardial oxidative stress and may decrease the 
activity of the mitochondrial complex in the myocardium [59]. In animal models, this was 
shown to lead to macro- and microvascular dysfunction [143] and to a remodelling of the 
myocardium [14, 16, 144, 145]. There is compelling evidence suggesting that binge drinking 
increase the risk of supraventricular arrhythmias [32, 65, 66, 77, 146-148]. To our 
knowledge, only one previous study examined the association between binge drinking and 
AF risk among light to moderate drinkers [149]. This study, conducted among cardiac 
patients found that binge drinkers who were otherwise moderate drinkers (drinking up to 21 
drinks per week) have similarly high risk of AF as those, who consume more than 21 drinks 
per week [149]. In Study IV, when we excluded individuals who consumed alcohol over the 
recommended limits, i.e., >seven drinks per week for women and >14 drinks per week for 
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men or who reported binge or problem drinking [82] we did not find an increased risk of AF. 
Studies examining the effects of acute alcohol infusion showed that alcohol binging may lead 
to cardiac arrhythmias through alteration in the electrophysiological properties of the 
myocytes by modifying ion-channel functions [32, 66, 146, 148]. Binge drinking stimulates 
the sympathetic nervous system and inhibits vagal activity, which also facilitates 
arrhythmogenic activities [32, 66, 146, 148].  
 The effect of beverage types  5.2.3
We did not find clear support for the hypothesis that the association of alcohol intake and the 
risk of HF and AF or with LV function differs by the type of alcoholic beverage. The inverse 
association between the quantity of alcohol intake and AMI risk was slightly weaker for beer 
consumption than for wine and spirit consumption. Though findings from earlier studies 
concerning differences in CVD risk according to the type of alcoholic beverages have not 
been fully consistent, it seems that ethanol is the active substance that may primarily be 
responsible for the anti-atherosclerotic effect [10, 13, 25, 74, 86]. Polyphenols, which are 
primarily found in wine, may have some additional health benefits, due to their antioxidant 
properties [88, 91, 94, 100]. Our finding that wine and spirits were similarly associated with 
AMI and HF risk is supportive of the hypothesis that alcohol is the active substance. The 
weaker association between beer and AMI risk than that observed in the case of the two other 
types of beverage may be due to its lowest alcohol content.  
 The role of AMI in the association between alcohol consumption and 5.2.4
HF risk  
A substantial proportion of HF cases have an ischemic aetiology [44] and HF is a common 
complication after AMI [44, 61]. More than one-third of AMI patients will eventually 
develop HF [44, 150]. As moderate alcohol consumption may slow down the atherosclerotic 
processes, the observed protective effect of light to moderate alcohol intake on HF risk may 
be mediated through IHD. Some studies conducted among AMI patients could not find an 
inverse association between light-moderate alcohol intake and HF risk [63, 151]. Other 
studies found that light to moderate alcohol intake was associated with a reduced HF risk 
only among HF cases with ischemic origin [61]. In our study, AMI partly mediated the 
association between alcohol intake and HF [152, 153]. This may indicate that mechanisms 
other than the anti-atherosclerotic properties of alcohol may contribute to the protective 
association between alcohol intake and HF. However, we cannot rule out the possibility that 
the inverse association was mediated by unmeasured IHD. 
5.3 THE BIOLOGICAL MECHANISMS BY WHICH LIGHT TO MODERATE 
ALCOHOL INTAKE MAY REDUCE THE RISK OF AMI AND HF 
Several biological mechanisms have been proposed to explain the link between light-
moderate alcohol intake and a lower risk of atherosclerosis. A large body of evidence shows 
that alcohol consumption is associated with an increased HDL cholesterol level in a dose-
response manner [88, 96, 98, 99] and that almost 50% of the protective effect of light-
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moderate alcohol consumption on IHD can be explained through its effect on HDL 
cholesterol [96, 98, 99]. On the other hand, a study from Norway, which pooled several large-
scale cohorts including the HUNT could not confirm that HDL cholesterol is a major 
mediator for the association between alcohol intake and cardiac mortality [154]. However, it 
should be noted, that cardiac mortality usually has lower specificity than hospital-based AMI 
diagnoses which might explain the discrepancy between this and most other studies. The 
mediating role of HDL cholesterol in the association between alcohol consumption and the 
risk of HF is less certain than in IHD [10, 25, 103, 155]. According to interventional studies, 
moderate alcohol intake may elevate HDL cholesterol and apolipoprotein-A levels [20, 88, 
91] by increasing the activity of lipoprotein lipase [96, 156] and decreasing the activity of 
cholesterol-ester-transfer protein [103, 157]. 
Light to moderate alcohol consumption is also associated with a better coagulation and 
fibrinolytic profile [96, 101, 103]. It may lower plasma fibrinogen and thromboxane-A levels 
and may inhibit platelet aggregation [18, 101]. Furthermore, moderate alcohol consumption 
may reduce the plasma concentrations of inflammatory markers, as C reactive protein and 
interleukin-6 [18, 88, 91, 100] and may improve endothelial function [76, 96]. Some studies 
suggest that the polyphenol content of alcoholic beverages in wine and beer may also have 
some additional anti-inflammatory effects [88, 90] and it may even modulate leukocyte 
adhesion [88, 90]. Light to moderate alcohol intake may improve insulin sensitivity and 
glycaemic control, most likely by increasing adiponectin production [20, 93, 96, 102-104]. 
Lastly, regular low-level alcohol intake may have a direct preconditioning effect on the 
myocytes which may contribute to the direct protective effect of low level alcohol intake on 
the myocardium [158]. It is also associated with a lower level of high-sensitivity cardiac 
troponin T, a marker of chronic subclinical myocardial damage [159]. 
5.4 METHODOLOGICAL CONSIDERATIONS 
There are many sources of potential bias that could influence the results of observational 
studies concerning the link between alcohol consumption and CVD. In the following section, 
we discuss the strengths and limitations of our studies. 
 Study design 5.4.1
Study I, II and IV had prospective designs that help to eliminate reverse causation and 
minimise recall bias. In study III, the main limitation was the cross-sectional design, which 
restricts causal inference. However, in study III we were able to detect subtle subclinical 
changes in the LV function before LV dysfunction may have caused clinical symptoms. 
Experiencing clinical symptoms might make some individuals decrease their alcohol 
consumption. 
 Selection bias 5.4.2
Due to the low net migration rate in the county [160] the biased loss to follow-up had little 
threat to validity [113, 123]. The participation rate was very high in HUNT1, and though it 
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dropped progressively in HUNT2 and HUNT3, it remained relatively high. However, 
selective participation is considered to be a lesser threat to validity in cohort than in case-
control studies [161]. In general, the participation rate was lower among men than among 
women and among those aged < 40 and > 80 years than among those aged 40-80 years. A 
non-participation study, conducted in a random sample of non-attendants in the HUNT2 
population showed that the main reason for non-participation among younger and middle 
aged individuals was lack of time or leaving the county [160]. The general reason for non-
participation among older individuals was that they already had regular health check-ups or 
that they had difficulties in going to the study centres due to health reasons [160]. A study 
which explicitly examined the non-response rate according to alcohol consumption categories 
found that abstainers were slightly more likely to be non-responders than individuals with 
other alcohol consumption habits [162]. The population of the Nord-Trøndelag county is 
socio-economically, ethnically and genetically homogenous, and the health-system in 
Norway is based on universal public insurance, providing similar high-quality service with 
equal accessibility to everyone independent of socio-economic status [113]. This makes it 
less likely that non-responders would substantially differ in variables that might affect our 
results considerably, however we cannot exclude, especially among older individuals, that a 
health-related selection mechanism influenced the participation.  
 Information bias 5.4.3
As in earlier studies using self-assessed information on alcohol, results might have been 
affected by a non-differential misclassification of the exposure. Self-reporting, which is the 
standard method to collect information on alcohol consumption in observational studies, 
tends to under-estimate alcohol intake in the higher categories, i.e., heavy drinkers 
systematically under-report their consumption [18, 25, 116, 163]. The effect of this 
systematic underreporting on the observed estimates might be twofold. First, it might classify 
some heavy drinkers into moderate drinkers, thus lowering the apparent threshold for harmful 
effect. Second, it may lead to an overestimation of the harmful effect or an underestimation of 
the protective effect among moderate drinkers.  
As ascertainment of the outcome was independent of the baseline measurements, it is less 
likely that the value of the outcome would be influenced by the value of the exposure. 
However, we cannot rule out that in study II individuals with a known alcohol use disorder 
might have been more likely to receive a diagnosis of HF than individuals without a history 
of alcohol use disorder. This might lead to over-estimation of the harmful effect of alcohol 
intake on HF risk among problem drinkers. AMI and HF cases were identified from the 
hospital discharge records and the National Cause of Death Register. The overall validity and 
reliability of the hospital-based diagnoses are high in the Nordic countries [164-166]. The 
specificity of the AMI diagnoses in the Norwegian Patient Register is 99.7% [167]. The 
specificity of the causes of death in the National Cause of Death Register is lower due to the 
relatively low rate of autopsy [168]. However, our results remained mostly the same when we 
excluded cases that were obtained only from the National Cause of Death Register. In study 
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III, we used high sensitivity tissue Doppler echocardiographic method that can detect subtle 
changes in LV function with high accuracy [114]. In study IV, AF diagnoses were identified 
from hospital medical records, and all diagnoses were validated by experts to ensure high 
specificity [121].  
 Confounding 5.4.4
We could adjust for a large number of potential confounders including smoking, physical 
activity, BMI, marital status, education, anxiety, depression, or common chronic disorders. 
Furthermore, in Norway, the socioeconomic differences are among the lowest in the world 
[123, 169]. Moreover, the health care system is equally accessible for all citizens regardless 
of socioeconomic status, this might minimise differences in healthcare accessibility due to 
socioeconomic position [123]. The population in Nord-Trøndelag is relatively homogenous 
both genetically and ethnically. 
One of the major strengths in our studies is that confounding due to social factors associated 
with alcohol consumption is likely to be lower than in studies conducted in other Western 
countries. Alcohol consumption is low in Norway by European standards, and it is unusually 
low in the Nord- Trøndelag County [118, 154]. Norway has a strict alcohol policy which 
includes high taxes on alcohol, limited availability of alcoholic beverages in state-owned 
shops, and an extensive public health effort to promote alcohol free-pubs, hotels, dance halls 
and restaurants [170]. Therefore, non-drinking is socially more accepted than in other 
Western societies [171]. Abstainers represent a considerably more healthy and socially less 
deprived group in Norway than in other countries, which reduces the likelihood of 
uncontrolled confounding by social pressure, social support and integration [172]. 
The “sick-quitter bias”, an important limitation in alcohol studies which did not assess 
previous alcohol intake can be described as a specific form of confounding by illness, where 
the exposure varies over time in response to changes in ill-health. One of the major strengths 
in our studies was the available information on alcohol consumption ten years before the 
baseline measurement. Therefore, it was possible to separate abstainers who were former 
drinkers from long-term abstainers.  
 Random error 5.4.5
Given the large sample size in our studies (studies I, II and IV), in general, we had a limited 
amount of random error. However, the distribution of specific variables, such as alcohol 
consumption was uneven. The majority of the participants reported consuming less than 
seven drinks per week which limited our possibility to draw conclusion regarding higher 
intake. In study III, the overall sample size was smaller, which further limited our 
possibilities to conduct subgroup analyses. 
 Generalizability  5.4.6
The distribution of different alcohol dehydrogenase gene variants has been shown to be 
different in Asia and Europe, [173, 174] These gene variants influence the speed of alcohol 
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metabolism, thus, our findings might not directly be generalizable to other ethnic groups, 
especially in Asian populations.  
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5.5 PUBLIC HEALTH IMPLICATIONS  
Methodological problems that may limit casual inference cannot fully be avoided, but the 
consistency of the results, together with the supporting evidence from experimental studies, 
and the plausibility of biological explanations endorse the hypothesis that light to moderate 
alcohol intake may be protective for some CVD. As randomised control trials in this area are 
lacking, public health recommendations concerning alcohol consumption can only rely on 
observational study results. There is an agreement that the initiation of alcohol consumption 
among non-drinkers should be avoided due to the risk of alcohol use disorder [83]. However, 
concerning habitual moderate alcohol consumption, public health consensus is missing, and 
recommendations and guidelines vary greatly [83, 175, 176]. While the WHO has a “less is 
better” policy toward alcohol consumption [177], many guidelines, based on the evidence on 
its cardio-protection, recommends alcohol consumption in moderation, usually up to 7-9 
drinks per week for women and 14 drinks per week and with a limitation of the amount on 
one drinking occasion [73, 82-84, 176].  
One major argument in favour of the zero consumption policy is that it is not clear how 
moderate alcohol intake affects the risk of several other diseases [12]. There is some evidence 
showing that even one-two drinks per day for women and two-three drinks per day for men 
increases the risk of liver injury [18, 178]. While light to moderate amount of alcohol 
consumption is not associated with a higher risk of most cancer, it may increase the risk of 
breast cancer in women and colorectal cancer in men [179]. However, it is possible that the 
observed, slightly elevated risk among moderate drinkers is due to binge drinking, as this 
increased risk of breast cancer cannot be found among low-level frequent drinkers [180]. The 
European Code Against Cancer recommends a maximum of 20g per day (~two drinks) for 
men and 10g (~one drink) per day for women, but preferably no alcohol consumption at all 
[181]. 
Another major limitation of the recommendations is based on net harm and net benefit of 
alcohol consumption, that the effect of alcohol intake may differ between individuals or 
ethnic groups [12]. Studies in India could not detect a beneficial effect of light to moderate 
alcohol intake on IHD risk, but it is not clear whether the lack of association was due to 
genetic characteristics or due to cultural factors and drinking patterns [1, 10, 29]. Genetic 
polymorphism of alcohol dehydrogenase genes as ADH1C or ADH1B may be important 
effect modifier for the association between light to moderate alcohol intake and IHD risk 
[182-185]. 
Finally, the population for which alcohol intake seems to be the most beneficial, i.e., 
individuals over 50 years, is usually broadly medicated with antihypertensive drugs, statins 
and beta-blockers. There is insufficient evidence available regarding the possible interactions 
between moderate amount of ethanol intake and different pharmaceuticals.  
Advising non-drinking to drinkers consuming alcohol within recommended limits, i.e., ≤ 7 
drinks per week for women and ≤ 14 drinks per men without binge drinking [82] may not be 
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advocated due to the strong evidence that supports the protective effect of low level, frequent 
drinking [10]. Our results support the recommendation that alcohol policy should rather focus 
on discouraging people from binge drinking which appears to be harmful even if it is 
occasional or if the average intake remains light to moderate [1, 10, 18]. The improvements 
of other protective factors than moderate alcohol consumption, such as healthy diet and 
moderate physical activity should be even more emphasized, as these methods are less 
disputed [4].  
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5.6 CONCLUSIONS 
In this thesis, we examined the association between light to moderate alcohol intake and the 
risk of AMI, HF and AF, while we could take care of some previous methodological 
shortcomings. We could confirm previous results that light to moderate alcohol intake was 
associated with a reduced risk of AMI and HF and a slightly increased risk of AF even when 
former drinking habits and confounding from several factors were taken into account. We 
found no evidence for a better LV function among light to moderate drinkers. When drinking 
pattern was taken into consideration, frequent low-level alcohol intake was associated with 
the lowest AMI and HF risk. Furthermore, the attributable risk of alcohol consumption within 
the recommended limits, i.e., ≤seven drinks per week for women and ≤14 drinks per week for 
men with no reported binge and/or problem drinking was negligible in this low-drinking 
population. On the other hand, among binge- and or problem drinkers, even if the average 
consumption level remained low, alcohol consumption was associated with slightly increased 
HF risk and a subtle sign of cardiac remodelling compared to abstainers. Our findings 
indicate that alcohol consumption within the recommended limits may provide some benefit 
on cardiovascular health.
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